-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 31, Huahai Pharmaceutical issued an announcement stating that the company had recently received a "drug registration certificate" for memantine hydrochloride tablets approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer's dementia
In November 2019, the company's application for drug registration of memantine hydrochloride tablets submitted to the Drug Evaluation Center of the National Medical Products Administration (hereinafter referred to as "the Evaluation Center of the National Medical Products Administration") was accepted (acceptance number: CYHS1900807); recently, The company received the "Drug Registration Certificate" for memantine hydrochloride tablets approved and issued by the State Food and Drug Administration
Memantine hydrochloride tablets are mainly used to treat moderate to severe Alzheimer's dementia
Up to now, the company has invested approximately RMB 3,318,200 in research and development projects for memantine hydrochloride tablets
According to relevant national policies, the company's memantine hydrochloride tablets are approved for production according to category 4 chemicals, which can be regarded as passing the consistency evaluation
